查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011273

避孕药市场：按类型、剂型、作用机制、材料类型、使用时长、使用频率、销售管道、应用和最终用户划分－全球市场预测（2026-2032 年）

Contraceptive Market by Type, Formulation, Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年避孕药具市场价值为411.3亿美元，预计到2026年将成长至441.3亿美元，复合年增长率为7.67%，到2032年将达到690.2亿美元。

主要市场统计数据
基准年（2025 年） 411.3亿美元
预计年份（2026年） 441.3亿美元
预测年份（2032年） 690.2亿美元
复合年增长率（） 7.67%

从策略角度审视现代避孕现状，并专注于创新、可及性、监管细微差别和以用户为中心的优先事项。

避孕市场正处于转折点，临床创新、不断变化的消费者期望以及政策环境的转变正在重塑产品开发和获取模式。生物医学技术和製药科学的进步正在扩大终端用户的选择范围，而数位健康平台和远端医疗正在改变避孕方法的发现、处方和获取方式。同时，关于生殖自主权和包容性的社会讨论正在影响需求模式和产品面临的监管审查。这些趋势要求价值链上的相关人员不仅要考虑有效性和安全性，还要考虑使用者体验、接受度和公平获取。

技术、分销、材料和监管实践方面的重大系统性变革正在重新定义避孕选择和交付模式。

过去十年间，技术进步、消费行为以及医疗保健系统优先事项的调整，共同推动了避孕领域的变革，重塑了避孕格局。长效可逆避孕方法在临床指引和实务上日益受到重视，生产者也更重视产品的持久性、易用性和副作用最小化。同时，荷尔蒙类和非荷尔蒙类避孕方法的进步——包括植入、注射剂、口服药物、经皮吸收贴片和屏障避孕法——拓宽了治疗选择，并实现了更个人化的护理路径。

该评估旨在评估主要市场的关税措施如何重组整个避孕供应链的采购、材料选择、库存计划和准入动态。

主要经济体在2025年征收关税，立即对全球避孕药具及其组件的供应链产生了连锁反应。从受影响地区采购原材料和组件的製造商面临更高的接收成本，被迫迅速调整筹资策略并实现供应商多元化。在许多情况下，契约製造製造商和成品製造商开始评估近​​岸外包、双重采购安排和库存策略，以减轻供应链中断的影响。因此，医院、药局和电经销商的前置作业时间和库存模式都受到了影响。

将产品类型、配方、作用机制、材料和最终用户概况与可操作的开发和商业策略联繫起来的精细细分洞察。

细分市场层面的差异化为产品开发和商业策略的优先排序提供了一个切实可行的框架。按类型划分，市场包括：事后紧急避孕药（分为子宫内避孕器和口服避孕药）；荷尔蒙疗法（包括植入式、注射式、口服和经皮给药）；非荷尔蒙疗法（以屏障避孕法为主）；草药和自然疗法（分为阿育同类疗法疗法和顺势疗法）；以及永久性避孕方法（例如输卵管结扎术和输精结扎术）。这些区分揭示了不同的临床路径。长效和永久性避孕方法通常需要专科护理和医疗采购，而口服避孕药、避孕贴片和屏障避孕法则通常涉及更广泛的基层医疗和零售管道。

区域策略挑战解释了监管多样性、文化规范、製造地和取得模式如何影响全球市场避孕措施的采用。

区域趋势对产品采纳、监管流程和分销模式有显着影响。在美洲，都市区先进的临床应用与农村地区医疗资源分配不均的现状形成了鲜明对比，这带来了双重挑战：一方面，医疗系统采购方需要投资高效长效的药物；另一方面，必须透过零售商和线上管道，为更广泛的人群提供便捷的药品获取途径。支付方方案和公共卫生计画决定了采购优先事项，而远端医疗的扩展也不断改变处方笺和配药方式。

竞争情报和企业策略揭示了创新、供应链韧性和数位服务如何重塑避孕药开发领域的领导地位。

竞争格局有利于那些能够整合差异化临床资产、稳健供应链和卓越病患服务的企业。主要企业正投资研发新一代荷尔蒙和非荷尔蒙製剂，加速开发长效製剂，并探索男性专用药物以拓展目标市场。研发公司、契约製造和分销合作伙伴之间的策略联盟日益普遍，这不仅能够加快规模扩张、拓宽分销管道，还能降低资本密集度。

高阶主管正在采取战术性和战略措施，以加强采购、加速材料创新、扩大数位化覆盖范围，并根据细分用户的需求调整产品组合。

产业领导企业应优先考虑几项协调一致的倡议，以确保短期稳定和长期成长。首先，供应商多元化和製定紧急采购计划可以降低贸易中断和关税波动带来的风险。双重采购和投资于经认证的区域供应商将提高营运柔软性。其次，加速非乳胶材料的开发和商业化可以解决过敏问题，扩大市场吸引力，同时降低单一材料类别的集中风险。第三，拓展数位化管道和远端医疗伙伴关係可以更好地适应不断变化的购买行为，并透过整合支援工具提高患者的用药依从性。

透过严格的混合方法研究途径检验了这些见解的有效性，该方法结合了相关人员访谈、文献整合、供应链映射和情境分析。

本分析所依据的研究结合了定性和定量方法，以确保其稳健性和可操作性。主要研究包括对临床医生、采购负责人、监管专家和分销主管进行结构化访谈，以获取关于临床应用、采购挑战和分销管道趋势的第一手观点。此外，还使用了包括同行评审的临床文献、监管文件、产品标籤和公开政策文件在内的二手资讯来检验临床和安全性声明。同时，供应链分析绘製了物料流向和製造地图，以评估贸易政策变化所带来的风险。

将技术、法规和供应链动态的变化转化为相关人员可操作的策略重点，并得出全面的结论。

总之，避孕市场正经历一场由技术进步、通路演变、材料创新和政策趋势共同驱动的重大变革。这些因素共同影响着临床实务和消费者行为。有效的策略应将临床差异化与营运韧性相结合，具体包括供应商多元化、在适当情况下采用非乳胶材料，以及整合数位化服务以满足使用者在各种就医地点的需求。鑑于区域差异和市场区隔的细微差别，需要采取个人化的方法，既要充分利用全球製造优势，也要尊重当地的监管环境和文化背景。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：避孕市场：依类型划分

  • 事后紧急避孕药
    • IUD
    • 口服避孕药
  • 荷尔蒙系统
    • 植入式避孕器
    • 注射式避孕药
    • 口服避孕药
    • 经皮避孕药
  • 非荷尔蒙系统
    • 障碍法
    • 草药避孕
      • 阿育吠陀
      • 同类疗法
    • 自然避孕法
  • 永恆的
    • 输卵管结扎
    • 血管结扎术

第九章：避孕药市场：以剂型划分

  • 修补
  • 丸
    • 单相型
    • 多相
  • 戒指

第十章：避孕药市场：依作用机转划分

  • 植入预防
  • 杀精作用
  • 抑制排卵

第十一章：避孕药具市场：依材质类型划分

  • 基于乳胶
  • 非乳胶
    • 丁腈橡胶
    • 聚异戊二烯
    • 聚氨酯

第十二章：避孕药市场：依持续时间划分

  • 长期
  • 短期

第十三章：避孕药市场：依使用频率划分

  • 必要时使用
  • 经常使用

第十四章 避孕药市场：依销售管道划分

  • 离线
    • 医院药房
    • 药局
  • 在线的
    • 电子商务平台
    • 网路药房

第十五章 避孕药市场：依应用领域划分

  • 一般
  • 性交后

第十六章 避孕药市场：依最终用户划分

  • 女士
    • 青少年
    • 成人
    • 停经后
  • 男性

第十七章 避孕药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章 避孕药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章 避孕药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第二十章：美国避孕药市场

第二十一章：中国避孕药市场

第22章 竞争情势

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • Abbvie, Inc.
  • Afaxys, Inc.
  • Agile Therapeutics
  • Bayer AG
  • China Resources（Group）Co., LTD.
  • Church & Dwight Co., Inc.
  • Cupid Limited
  • Helm AG
  • Johnson & Johnson Services, Inc.
  • Organon Group of Companies
  • Pfizer Inc.
  • Veru, Inc.
  • Viatris Inc.
Product Code: MRR-4316E4E895C4

The Contraceptive Market was valued at USD 41.13 billion in 2025 and is projected to grow to USD 44.13 billion in 2026, with a CAGR of 7.67%, reaching USD 69.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.13 billion
Estimated Year [2026] USD 44.13 billion
Forecast Year [2032] USD 69.02 billion
CAGR (%) 7.67%

A strategic orientation to the modern contraceptive environment highlighting innovation, access, regulatory nuance, and user-centric priorities

The contraceptive landscape stands at an inflection point where clinical innovation, shifting consumer expectations, and evolving policy environments converge to reshape product development and access. Advances in biomedical technologies and formulation science are expanding the range of options available to end-users, while digital health platforms and telemedicine are changing how contraception is discovered, prescribed, and obtained. At the same time, societal conversations around reproductive autonomy and inclusivity are influencing both demand patterns and the regulatory scrutiny that products face. These dynamics require stakeholders across the value chain to consider not only efficacy and safety, but also user experience, acceptability, and equity of access.

Transitioning from legacy product portfolios to a future-ready mix requires a deep understanding of clinical differentiation and end-user segmentation. Health systems and payers are emphasizing long-term outcomes and cost-effective care pathways, which in turn affects procurement strategies and formulary decisions. Simultaneously, manufacturers and innovators must navigate complex supply chains, regulatory compliance, and sustainability considerations while accelerating next-generation product development. The combination of these forces creates both significant opportunities for targeted innovation and acute operational risks for organizations that are slow to adapt. Accordingly, this introduction frames the broader patterns that inform the remainder of the analysis and sets the stage for practical recommendations that align scientific progress with real-world access and commercial viability.

Key systemic shifts in technology, distribution, materials, and regulatory practice that are redefining contraceptive choice and delivery models

Over the last decade, several transformative shifts have redefined the contraceptive landscape, driven by converging advances in technology, consumer behavior, and health system priorities. Long-acting reversible contraception has become more prominent in clinical guidelines and practice, prompting manufacturers to emphasize durability, ease of insertion, and minimized side effects. Concurrently, progress in hormonal and non-hormonal formulations-spanning implantables, injectables, oral systems, transdermal patches, and barrier methods-has broadened therapeutic choices, enabling more personalized care pathways.

Digital and distribution innovations have accelerated change by lowering friction for prescription access and adherence support. Telehealth consultations combined with e-commerce and online pharmacy fulfillment are altering the balance between traditional clinical settings and consumer-facing channels. At the same time, material science improvements, including alternatives to conventional latex products, are creating opportunities to address allergy concerns and enhance user comfort. Regulatory landscapes have adjusted to accommodate these innovations, yet also introduce complexity around clinical endpoints, post-market surveillance, and cross-border distribution. Taken together, these shifts are not incremental; they change how products are developed, marketed, and delivered, forcing stakeholders to rethink clinical engagement, patient education, and supply chain resilience in an increasingly interconnected ecosystem.

Assessing how tariff measures in major markets have reshaped sourcing, materials choices, inventory planning, and access dynamics across contraceptive supply chains

The introduction of tariff measures by a major economy in 2025 created immediate reverberations across global supply chains for contraceptive products and their constituent materials. Manufacturers sourcing raw materials or components from affected jurisdictions faced higher landed costs, prompting rapid reassessment of procurement strategies and supplier diversification. In many cases, contract manufacturers and finished-goods producers began evaluating nearshoring options, dual-sourcing arrangements, and stockpiling approaches to mitigate disruption, which in turn affected lead times and inventory models for hospitals, pharmacies, and e-commerce distributors.

Beyond procurement, tariff-related cost pressures influenced strategic decisions concerning product formulation and material selection. For example, supply chain sensitivities accelerated interest in non-latex alternatives such as nitrile, polyisoprene, and polyurethane for barrier products, as firms sought materials with more robust multi-region supply bases. Regulatory compliance costs and customs delays also introduced friction for time-sensitive product launches and for emergency contraceptives that require rapid distribution channels. Clinicians and health systems experienced operational strain when procurement timelines shifted, while payers and purchasing groups began scrutinizing total cost implications, including the downstream effects on patient access. The aggregate effect has been to heighten the importance of supply chain transparency, contractual flexibility, and strategic sourcing as core competencies for companies operating in the contraceptive arena.

Granular segmentation insights that connect product types, formulations, modes of action, materials, and end-user profiles to actionable development and commercial strategies

Segment-level differentiation offers a pragmatic framework for prioritizing product development and commercial strategies. By Type, the market encompasses emergency contraceptives divided into intrauterine devices and pills, hormonal methods including implantable, injectable, oral and transdermal options, non-hormonal approaches featuring barrier methods as well as herbal choices split into Ayurvedic and homeopathic traditions and natural methods, and permanent solutions such as tubal ligation and vasectomy. These distinctions reveal divergent clinical pathways: long-acting and permanent options tend to engage specialist care and health-system procurement, whereas pills, patches, and barrier methods often interact with broader primary care and retail channels.

Considering Formulation, patch, pill and ring formats carry different adherence and acceptability profiles; within pills, the distinction between monophasic and multiphasic regimens informs counseling and side-effect management. Mode of Action segmentation-preventing implantation, spermicidal action, and suppression of ovulation-connects directly to clinical outcomes and patient education priorities, shaping labeling and safety monitoring. Material Type splits into latex-based and non-latex offerings, with the latter subdivided into nitrile, polyisoprene, and polyurethane, each presenting trade-offs in cost, tactile properties, and allergenicity.

Duration and Usage Frequency segmentation-long-term versus short-term and on-demand versus regular use-highlight pathways for engagement and adherence interventions, while Sales Channel distinctions between offline outlets such as hospital pharmacies and retail pharmacies and online channels including e-commerce platforms and online pharmacies underscore shifting acquisition behaviors. Application differentiates general use from post-coital use, signaling differing urgency and distribution requirements. End-User segmentation recognizes female and male cohorts, with further granularity for females across adolescent, adult, and post-menopausal groups, which affects clinical guidance, marketing tone, and packaging. Together, these segmentation lenses provide a cohesive map for aligning product features, regulatory strategy, and go-to-market execution to specific clinical and consumer needs.

Regional strategic imperatives describing how regulatory diversity, cultural norms, manufacturing hubs, and access models shape contraceptive deployment across global markets

Regional dynamics exert a substantial influence on product adoption, regulatory pathways, and distribution models. In the Americas, a mix of advanced clinical adoption in urban centers and uneven access across rural communities creates a dual imperative: invest in both high-efficacy long-acting options for health-system purchasers and accessible retail and online offerings for broader populations. Payer systems and public health programs shape procurement priorities, and telemedicine expansion continues to alter how prescriptions are issued and fulfilled.

Across Europe, Middle East & Africa, regulatory heterogeneity and cultural diversity require nuanced market entry strategies. Regulatory frameworks in parts of Europe emphasize rigorous clinical evidence and post-market surveillance, while certain countries in the Middle East and Africa prioritize local manufacturing incentives and public-sector distribution. These conditions influence decisions around clinical trial design, labeling, and partnership models. In many markets, cultural attitudes toward contraception and the role of community health workers affect adoption patterns, especially for non-hormonal and herbal alternatives.

The Asia-Pacific region presents a broad spectrum from highly industrialized supply hubs to markets with strong traditional medicine use and distinct consumer preferences. Manufacturing capacity in parts of Asia-Pacific supports global supply chains for materials and finished goods, yet local regulatory expectations and reimbursement practices vary substantially. Traditional herbal practices in some locales create parallel demand channels that companies must understand and engage with respectfully. Overall, regional strategies must balance centralized manufacturing efficiencies with local regulatory compliance and culturally informed commercial approaches to ensure both access and acceptance.

Competitive intelligence and corporate strategies revealing how innovation, supply chain resilience, and digital services are reshaping leadership in contraceptive development

Competitive dynamics favor organizations that combine differentiated clinical assets with resilient supply chains and compelling patient-facing services. Leading companies are investing in next-generation hormonal and non-hormonal formulations, accelerating work on long-acting modalities, and exploring male-targeted agents to broaden addressable markets. Strategic alliances between developers, contract manufacturers, and distribution partners are increasingly common, enabling faster scale-up and broader channel reach while mitigating capital intensity.

Other firms are differentiating through material innovation and user experience redesign, optimizing tactile properties, packaging, and instructions for use to improve acceptability and adherence. Digital capabilities, including telehealth integrations, adherence support tools, and e-pharmacy partnerships, are becoming core competitive levers that drive customer acquisition and retention. At the same time, companies with strong regulatory affairs capabilities and diverse manufacturing footprints are better positioned to absorb policy and tariff-driven shocks. Emerging entrants that combine clinical novelty with agile commercialization models present both competition and opportunity for incumbents seeking acquisition targets or partnerships to fill portfolio gaps. Overall, the competitive landscape is shifting from purely product-centric competition to ecosystem competition where service, supply chain reliability, and regulatory agility matter as much as clinical differentiation.

Tactical and strategic actions for executives to strengthen sourcing, accelerate material innovation, expand digital reach, and align portfolios with segmented user needs

Industry leaders should prioritize several coordinated actions to secure both short-term stability and long-term growth. First, diversifying the supplier base and developing contingency sourcing plans will reduce exposure to trade disruptions and tariff volatility; investing in dual-sourcing and qualified regional suppliers enhances operational flexibility. Second, accelerating development and commercialization of non-latex materials will address allergy concerns and broaden market appeal, while simultaneously reducing concentration risk tied to single material classes. Third, expanding digital channels and telehealth partnerships will capture shifting acquisition behavior and improve adherence through integrated support tools.

In parallel, companies should tailor product portfolios and messaging to specific segments identified earlier, aligning clinical attributes with end-user needs such as adolescent education, adult convenience, or post-menopausal safety considerations. Engaging proactively with regulators and payers to clarify evidence requirements and reimbursement pathways will smooth market entry and reduce launch uncertainty. Finally, embedding sustainability and ethical sourcing into procurement and manufacturing decisions will protect brand reputation and respond to growing stakeholder expectations. These actions, taken together, form a pragmatic roadmap for leaders seeking to balance innovation with operational resilience and customer-centric commercialization.

A rigorous mixed-methods research approach combining stakeholder interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights

The research underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with clinicians, procurement officers, regulatory specialists, and distribution executives to capture first-hand perspectives on clinical adoption, sourcing challenges, and channel dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, product labels, and publicly available policy documents to validate clinical and safety-related assertions. In addition, supply chain analyses mapped material flows and manufacturing footprints to assess vulnerability to trade policy shifts.

Analytical methods included cross-segmentation synthesis to align product attributes with end-user needs and scenario analysis to examine the implications of policy changes and supply-chain disruptions. Findings were triangulated across data sources and expert review to minimize bias and enhance credibility. Limitations of the methodology include variability in region-level data quality and the evolving nature of regulatory guidance, which necessitate periodic updates to maintain relevance. Ethical considerations guided the engagement with clinical experts and respect for cultural contexts when discussing traditional and herbal contraceptive practices. Together, these methods produced a defensible framework for the insights and recommendations presented in this report.

Summative conclusions that translate the evolving technological, regulatory, and supply chain dynamics into pragmatic strategic priorities for stakeholders

In closing, the contraceptive landscape is undergoing meaningful transformation driven by technological progress, evolving distribution channels, materials innovation, and policy dynamics that together influence clinical practice and consumer behavior. Effective strategies will combine clinical differentiation with operational resilience-diversifying suppliers, embracing non-latex materials where appropriate, and integrating digital services to meet users where they seek care. Regional nuances and segmentation layers call for tailored approaches that respect local regulatory and cultural contexts while leveraging global manufacturing strengths.

Stakeholders that act decisively to align product portfolios with clearly defined end-user needs, while strengthening supply chain transparency and regulatory engagement, will be best positioned to capture long-term value. The insights and recommendations offered here are designed to help executives, clinical leaders, and commercial teams convert complexity into opportunity, supporting decisions that improve access, enhance user experience, and sustain innovation in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Market, by Type

  • 8.1. Emergency Contraceptives
    • 8.1.1. IUDs
    • 8.1.2. Pills
  • 8.2. Hormonal
    • 8.2.1. Implantable Contraceptives
    • 8.2.2. Injectable Contraceptives
    • 8.2.3. Oral Contraceptives
    • 8.2.4. Transdermal Contraceptives
  • 8.3. Non-Hormonal
    • 8.3.1. Barrier Methods
    • 8.3.2. Herbal Contraceptives
      • 8.3.2.1. Ayurvedic
      • 8.3.2.2. Homeopathic
    • 8.3.3. Natural Methods
  • 8.4. Permanent
    • 8.4.1. Tubal Ligation
    • 8.4.2. Vasectomy

9. Contraceptive Market, by Formulation

  • 9.1. Patch
  • 9.2. Pill
    • 9.2.1. Monophasic
    • 9.2.2. Multiphasic
  • 9.3. Ring

10. Contraceptive Market, by Mode Of Action

  • 10.1. Prevent Implantation
  • 10.2. Spermicidal Action
  • 10.3. Suppress Ovulation

11. Contraceptive Market, by Material Type

  • 11.1. Latex-Based
  • 11.2. Non-Latex
    • 11.2.1. Nitrile
    • 11.2.2. Polyisoprene
    • 11.2.3. Polyurethane

12. Contraceptive Market, by Duration

  • 12.1. Long-Term
  • 12.2. Short-Term

13. Contraceptive Market, by Usage Frequency

  • 13.1. On-Demand
  • 13.2. Regular Use

14. Contraceptive Market, by Sales Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Pharmacy
  • 14.2. Online
    • 14.2.1. E-Commerce Platforms
    • 14.2.2. Online Pharmacy

15. Contraceptive Market, by Application

  • 15.1. General Use
  • 15.2. Post-Coital Use

16. Contraceptive Market, by End-User

  • 16.1. Female
    • 16.1.1. Adolescent
    • 16.1.2. Adult
    • 16.1.3. Post-Menopausal
  • 16.2. Male

17. Contraceptive Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Contraceptive Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Contraceptive Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Contraceptive Market

21. China Contraceptive Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbvie, Inc.
  • 22.6. Afaxys, Inc.
  • 22.7. Agile Therapeutics
  • 22.8. Bayer AG
  • 22.9. China Resources (Group) Co., LTD.
  • 22.10. Church & Dwight Co., Inc.
  • 22.11. Cupid Limited
  • 22.12. Helm AG
  • 22.13. Johnson & Johnson Services, Inc.
  • 22.14. Organon Group of Companies
  • 22.15. Pfizer Inc.
  • 22.16. Veru, Inc.
  • 22.17. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 323. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. ASEAN CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. ASEAN CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 344. GCC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 345. GCC CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 347. GCC CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 348. GCC CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 349. GCC CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 350. GCC CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 351. GCC CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 352. GCC CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 353. GCC CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 354. GCC CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. GCC CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 356. GCC CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 357. GCC CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 358.